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The mammalian target of rapamycin (mTOR) serine/threonine
kinase is the catalytic subunit of two multi-protein complexes,
referred to as mTORC1 and mTORC2. Signaling downstream
of mTORC1 has a critical role in leukemic cell biology by
controlling mRNA translation of genes involved in both cell
survival and proliferation. mTORC1 activity can be down-
modulated by upregulating the liver kinase B1/AMP-activated
protein kinase (LKB1/AMPK) pathway. Here, we have explored
the therapeutic potential of the anti-diabetic drug, metformin
(an LKB1/AMPK activator), against both T-cell acute lympho-
blastic leukemia (T-ALL) cell lines and primary samples
from T-ALL patients displaying mTORC1 activation. Metformin
affected T-ALL cell viability by inducing autophagy and
apoptosis. However, it was much less toxic against proliferat-
ing CD4þ T-lymphocytes from healthy donors. Western blot
analysis demonstrated dephosphorylation of mTORC1 down-
stream targets. Unlike rapamycin, we found a marked inhibition
of mRNA translation in T-ALL cells treated with metformin.
Remarkably, metformin targeted the side population of T-ALL
cell lines as well as a putative leukemia-initiating cell sub-
population (CD34þ /CD7/CD4) in patient samples. In conclu-
sion, metformin displayed a remarkable anti-leukemic activity,
which emphasizes future development of LKB1/AMPK activa-
tors as clinical candidates for therapy in T-ALL.
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Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
hematologic cancer caused by malignant transformation of
developing T cells in the thymus. T-ALL accounts for 10–15%
and 25% of pediatric and adult ALL, respectively.1 After
the introduction of intensified polychemotherapy schemes, a
remarkable improvement has been observed in the prognosis of
T-ALL patients, especially in children and adolescents. Never-
theless, the outcome of relapsed and chemoresistant T-ALL
remains dismally disappointing.2 Therefore, novel and less toxic
treatment strategies are needed that may target aberrantly
activated signaling pathways influencing proliferation, survival
and drug resistance of T-ALL cells.3–6 About 85% of T-ALL
patients display increased phosphatidylinositol 3-kinase (PI3K)/
Akt/mammalian target of rapamycin (mTOR) activation at
diagnosis, and this has a negative prognostic impact.7–9 mTOR
exists in two complexes that comprise distinct sets of protein-
binding partners. mTORC1, defined by the interaction between
raptor (regulatory-associated protein of mTOR) and mTOR, is
sensitive to rapamycin/rapalogues and is thought to mediate
many of its downstream effects through p70S6 kinase (p70S6K),
S6 ribosomal protein (S6RP) and initiation factor 4E-binding
protein 1 (4E-BP1).10 mTORC2, defined by the interaction
between mTOR and Rictor (rapamycin-insensitive companion
of mTOR), is considered to be rapamycin resistant and
phosphorylates Akt at Ser 473, one of two phosphorylated
residues required for full Akt activation.10 Upregulated
mTORC1 activity within cancer cells increases the synthesis of
many oncogenic proteins controlled at the translation initiation
level, through the phosphorylation of the physiologic translation
repressor 4E-BP1 at multiple residues.11,12 An important
regulator of the mTORC1-dependent translation process is the
liver kinase B1 (LKB1)/AMP-activated protein kinase (AMPK)
axis. LKB1 is a serine/threonine protein kinase encoded by the
STK11 gene, originally identified as the gene mutated in the rare
autosomal dominant human genetic disorder, Peutz–Jeghers
syndrome.13 Peutz–Jeghers syndrome patients develop numer-
ous benign tumors (classed as hamartomas) in the gastrointest-
inal tract and have a 20-fold increased risk of developing
malignant tumors at other sites, whereas mutations in the LKB1
gene are also seen in some sporadic cancers, especially lung
adenocarcinoma.14 Therefore, LKB1 is a classical tumor
suppressor. AMPK is a direct LKB1 substrate.15 A consequence
of AMPK activation by LKB1 is the inhibition of the mTORC1
pathway through phosphorylation of tuberous sclerosis 2 or
hamartin and raptor.16,17 Metformin (N,N-dimethylbiguanide)
belongs to the biguanide class of oral hypoglycemic agents and
has been widely used in treatment of Type 2 diabetes for many
years. Intriguingly, there is a growing body of evidence that
metformin reduces cancer risk and that it does so through
activation of AMPK and repression of mTORC1.18 In light of
these findings, metformin is now being tested in several clinical
trials in patients with solid tumors, especially breast cancer.19
A recent paper has highlighted the cytotoxicity of metformin in
preclinical models of acute myelogenous leukemia (AML),20
emphasizing the effects of metformin on the translation of
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oncogenic proteins. We have recently demonstrated that
inhibition of mTORC1-mediated oncogenic protein transla-
tion occurs also in T-ALL cells treated with mTORC1/mTORC2
ATP-competitive inhibitors, but not with rapamycin.12 Here, we
show that in T-ALL cell lines and patient primary cells, the LKB1/
AMPK tumor-suppressor pathway is functional and can be
activated by metformin treatment. Accordingly, metformin
displayed a strong cytotoxic activity against both T-ALL cell
lines and lymphoblasts from the T-ALL patients but barely
affected the proliferation of peripheral blood CD4þ T-lympho-
cytes from healthy donors. Moreover, metformin blocked the
catalytic activity of mTORC1 and markedly repressed mRNA
translation, resulting in decreased expression of highly onco-
genic proteins. Treatment of T-ALL cells with metformin induced
both autophagy and apoptosis. Remarkably, metformin targeted
T-ALL subpopulations, which might correspond to leukemia-
initiating cells (LIC). Taken together, our findings suggest
that targeting AMPK-mTORC1 signaling may be an interesting
option for treating T-ALL cases that display an LKB1/AMPK
inducible pathway and depend on aberrant upregulation of
mTORC1 for their proliferation and survival.
Materials and methods
Materials
Metformin was purchased from Sigma-Aldrich (St Louis,
MO, USA). The PI3K-selective inhibitor, GDC-0941, was from
Axon Medchem BV (Groningen, The Netherlands). For western
blotting analysis, primary antibodies and peroxidase-conjugated
secondary antibodies were purchased from Cell Signaling Tech-
nology (Danvers, MA, USA). For flow cytometric analysis,
AlexaFluor 488-conjugated antibodies to Ser 473 p-Akt, Thr
37/46 p-4E-BP1 and Ser 235/236 p-S6RP were obtained from
Beckman Coulter (Miami, FL, USA). A blocking monoclonal
antibody to the insulin-like growth factor-1 receptor (clone aIR3)
was purchased from Thermo Fisher Scientific (Rockford, IL,
USA) and was employed at 5mg/ml.
Cell culture and primary samples
The T-ALL cell lines Jurkat, MOLT-4, CEM-R (drug-resistant cells
overexpressing 170-kDa P-glycoprotein),21 RPMI-8402 and
BE-13 were grown in RPMI 1640, supplemented with 10% fetal
bovine serum. Patient samples or peripheral blood CD4þ
T-lymphocytes from healthy donors were obtained with
informed consent according to the Institutional guidelines and
isolated using Ficoll-Paque (Amersham Biosciences, Little
Chalfont, UK) for patient lymphoblasts or magnetic labeling
(Miltenyi Biotec, Bergisch Gladbach, Germany) for CD4þ
T-lymphocytes. CD4þ T-lymphocytes (105/well) were cultured
in RPMI 1640 media containing 10% fetal bovine serum and
stimulated for 48 h with a mixture of 10mg/ml phytohemagglu-
tinin (PHA-M) and 50 ng/ml human recombinant interleukin-2
to induce proliferation. Then, 1 mCi (0.037 MBq) [3H]-thymidine
was added for 16 h. The amount of radioactivity incorporated
was determined by trichloracetic acid precipitation.
Cell viability analysis
MTT (3-(4,5-dimethylthythiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assays were performed to assess the sensitivity of cell
lines or patient samples to metformin, as previously reported.22
Results were statistically analyzed by GraphPadPrism Software
(GraphPad Software Inc., version 3.2, San Diego, CA, USA).
[3H]-thymidine incorporation
T-ALL cells were incubated for 48 h in triplicate at 105/ml.
They were then pulsed for 6 h with 1mCi (0.037 MBq/ml)
[3H]-thymidine. The amount of radioactivity incorporated was
determined as outlined above. For each sample, [3H]-thymidine
incorporation was set at 100% in the control, and was expressed
relative to this value in the presence of the drugs.
Western blot analysis
This was performed as detailed elsewhere.23 Analysis with an
antibody to b-actin demonstrated equal protein loading.
Transmission electron microscope analysis
This was performed according to standard techniques, as
described previously.12
Polysome analysis, [3H]-leucine incorporation and
7methyl-GTP cap affinity assay
These were performed as reported elsewhere.12
Quantitative real-time PCR on mRNAs polysome
fractions
The nonpolysome and polysome-containing fractions were
pooled and analyzed by quantitative real-time PCR for c-Myc
and Bcl-xL mRNAs. Results are expressed as fold change of
polysomal-bound mRNA relative to the total mRNA amount.24
The housekeeper gene used was human b-actin. Primers
used were: c-Myc forward primer: 50-GGAACTCTTGTGCGTA
AGGA-30; c-Myc reverse primer: 50-CAAGACTCAGCCAAGGTT
GTG-30; Bcl-xL forward primer: 50-GTTGAAGCGTTCCTGGC
CCTTT-30; Bcl-xL reverse primer: 50-CAGAATGGACTGGACTG
AATCGGAGAT-30; b-actin forward primer: 50-TCCCTGGAGAA
GAGCTACGA-30; b-actin reverse primer: 50-AGCACTGTGTT
GGCGTACAG-30.
Flow cytometric detection of T-ALL side population
cells
This was performed as reported elsewhere,25 using a Cell Lab
Quanta SC flow cytometer (Beckman Coulter) equipped with an
UV lamp and a 488-nm solid-state laser.
Flow cytometric analysis of p-Akt, p-4E-BP1 and p-S6RP
levels, and of putative LIC in T-ALL patient samples
These analyses were performed as detailed elsewhere,12 using a
Navios flow cytometer (Beckman Coulter), equipped with
Kaluza software. At least 5000 events per sample were acquired.
Statistical evaluation
The data are presented as mean values from three separate
experiments±s.d. Data were statistically analyzed by a
Dunnet’s test after one-way analysis of variance at a level
of significance of Po0.05 or Po0.001 vs control samples.
Results
Metformin has cytotoxic effects on T-ALL cell lines
The effects of metformin on T-ALL cells were analyzed by
treating the cells with increasing concentrations of the drug and
analyzing the rates of proliferation by 48 h MTT assays
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Figure 2 Effects of metformin on the phosphorylation of PKCz/AMPKa and critical components of the mTORC1 signaling pathway. Cell lines
were incubated for the indicated times in the presence of 5 mM metformin. (a) Western blot analysis documented increased levels of Thr 172
p-AMPKa in all cell lines, except for Jurkat, and an mTORC1 signaling inhibition in all cells was considered. (b) CEM-R and RPMI-8402 were
analyzed by western blotting for Thr 410/403 p-PKCz and total PKCz. (c) Levels of Ser 473 p-Akt and Akt were investigated by western blot analysis
in Jurkat and CEM-R cells. (d) Western blot analysis for Ser 473 p-Akt, Akt and IRS2 in CEM-R cells treated with metformin alone (5 mM), or with
metformin plus either GDC-0941 (GDC) or aIR3 at the indicated concentrations. CTRL: untreated cells. (e) Jurkat and CEM-R cells were grown in
the presence of metformin alone (5 mM) or with metformin plus either GDC-0941 (GDC) or aIR3 at the indicated concentrations for 48 h. They
were then pulsed for 6 h with [3H]-thymidine. For each sample, [3H]-thymidine incorporation was set at 100% in the control (CTRL) and was
expressed relative to this value in the presence of the drugs. Asterisks indicate significant differences (Po0.01) relative to untreated cells.
Figure 1 Metformin affects viability of T-ALL cell lines. (a) MTT assays of T-ALL cell lines treated with increasing concentrations of metformin for
48 h. Results are the mean of at least three different experiments±s.d. (b) CD4þ T-lymphocytes isolated from the peripheral blood of healthy
donors and stimulated with PHA-M plus interleukin-2, were treated with increasing concentrations of metformin. One representative of three
different experiments is shown. Maximal incorporation of [3H]-thymidine was 73 888 c.p.m., 66 007 c.p.m. and 84 112 c.p.m. for donor 1, 2 and 3,
respectively. s.d. was o15%.
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(Figure 1a). Cell lines displayed an IC50 (half maximal inhibitory
concentration) for metformin ranging from 1.6 to 5.6 mM.
The drug-resistant CEM-R cell line displayed the highest
sensitivity to metformin. In contrast, CD4þ T-lymphocytes
isolated from the peripheral blood of healthy donors and stimu-
lated with PHA-M plus interleukin-2, were much less sensitive
to metformin concentrations as high as 10 mM as far as their
proliferation (assayed by [3H]-thymidine incorporation) was
concerned (Figure 1b). Overall, these findings demonstrated
that metformin reduced the growth of T-ALL cell lines. More-
over, they also suggested metformin could have a favorable
therapeutic index, as it affected proliferation of normal CD4þ
T-lymphocytes to a much lower extent.
The LKB1/AMPK axis is functional and controls
mTORC1 activity in T-ALL cells
Western blot analysis demonstrated a time-dependent increase
in Thr 172 p-AMPKa, after treatment with 5 mM metformin in
BE-13, CEM-R and RPMI-8402 cell lines. Increased p-AMPK
levels were accompanied by increased phosphorylation of
Ser 792 p-raptor. Although Jurkat cells did not present an
evident increase in AMPKa phosphorylation, they displayed a
marked increase in Ser 792 p-raptor levels (Figure 2a), an event
directly mediated by AMPKa.17 In agreement with increased
Ser 792 raptor phosphorylation, we found that metformin
inhibited the phosphorylation of mTORC1 downstream sub-
strates Thr 37/46 p-4E-BP1, Thr 389 p-p70S6K and Ser 235/236
p-S6RP (Figure 2a).
It has been reported that metformin-mediated inhibition of
complex I of the mitochondrial respiratory chain results in the
generation of reactive nitrogen species that activate protein
kinase C (PKC) z, which, in turn, phosphorylates and upregulates
LKB1.26 As PKCz requires phosphorylation on Thr 410/403 for
its activation, we examined the levels of this phosphorylated
amino-acid residue after metformin treatment. As shown in
Figure 2b, metformin treatment resulted in increased phosphor-
ylation of these threonine residues of PKCz, a result that attests
to the stimulation of the PKCz/LKB1/AMPKa pathway.
As it is known that inhibition of p70S6K phosphorylation in
AML cells could relieve an inhibitory loop on Akt, which
involves the IGF-1R and the insulin receptor substrate (IRS) 2,27
the levels of Ser 473 p-Akt were analyzed in response to
metformin. As shown in Figure 2c, in Jurkat cells metformin
actually decreased phosphorylation of Ser 473 p-Akt. However,
in CEM-R cells, the phosphorylation of this amino-acid residue
markedly increased in response to metformin. This phenomenon
was dependent on both PI3K and IGF-R1, as either a PI3K-
selective inhibitor, GDC-0941, or a blocking antibody to the
IGF-1R (aIR3) blunted the metformin-induced hyperphos-
phorylation of Akt. Moreover, metformin resulted in increased
levels of IRS2 protein expression in CEM-R cells (Figure 2d).
Thus, we investigated whether the combination of metformin
plus either GDC-0941 or aIR3 was more effective than
metformin alone in reducing the proliferation rate of CEM-R
cells, as assessed by [3H]-thymidine incorporation. As expected,
the combined treatments were more effective in reducing
proliferation of CEM-R, but not of Jurkat, cells (Figure 2e).
Overall, our findings documented that metformin was effec-
tive in downregulating mTORC1 signaling in T-ALL cells, most
notably resulting in dephosphorylation of the translation
repressor 4E-BP1. However, they also demonstrated that in
CEM-R cells metformin could hyperactivate Akt, which could
then decrease its anti-proliferative efficacy.
Metformin induces autophagy and apoptosis in
T-ALL cell lines
As mTORC1 is an inhibitor of autophagy, it was investigated
whether metformin could indeed induce autophagy in T-ALL
Figure 3 Metformin induces autophagy and apoptosis in T-ALL cell lines. (a) CEM-R and BE-13 cell lines were treated for the indicated times
with 5 mM metformin, then processed for transmission electron microscope analysis that documented autophagy and apoptosis induction.
Arrows indicate cytoplasmic vacuoles containing various degraded organelles, whereas arrowheads highlight condensed apoptotic chromatin.
CTRL: untreated cells. (b) Western blot analysis was carried out for LC3B I/II in T-ALL cells treated with 5 mM metformin for the indicated times.
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cells. Induction of autophagy was confirmed by transmission
electron microscope analysis, the gold standard for autophagy
studies,28 which documented the presence of autophagic
vacuoles in the cytoplasm of metformin-treated CEM-R and
BE-13 cells (Figure 3a). However, ultrastructural analysis after
metformin treatment also revealed the presence of apoptotic
cells (Figure 3a). To confirm induction of autophagy, we studied
the cleavage of LC3B, which is the only known mammalian
protein that stably associates with the autophagosome mem-
branes.29 Indeed, LC3B can be detected as LC3B-I (cytosolic)
and LC3B-II (membrane bound and enriched in the autophagic
vacuole fraction) forms. Metformin treatment caused an increase
in LC3B-II (cleaved fragment; Figure 3b).
Metformin inhibits mRNA translation in T-ALL cells
We performed polysome analysis using Jurkat cells treated with
either rapamycin or metformin. Polysomes were separated
through sucrose density gradients, and their profiles were gene-
rated by the measurement of absorbance at 254 nm. Metformin
caused an inhibition of translation initiation, as documented by
the shift from large to small polysomes. In contrast, rapamycin
had no effects (Figure 4a). The impact of metformin on protein
synthesis was further evaluated by (3H)-leucine incorporation
into neo-synthesized proteins of Jurkat and CEM-R cells. The
drug was able to reduce proteins synthesis, whereas rapamycin
did not significantly affect it (Figure 4b). Translation of mRNA is
tightly regulated at the initiation level through the assembly of
eIF4F complexes.30 Using Jurkat cells, we compared the effects
of rapamycin and metformin on eIF4F assembly by pull-down
assays using 7methyl-GTP-Sepharose beads that mimic the cap
structure of mRNA.20 While exposure to metformin dissociated
eIF4G from eIF4E and increased the amount of 4E-BP1 bound
to eIF4E, indicating inhibition of eIF4F complex assembly,
treatment with rapamycin did not change the amount of eIF4G
or 4E-BP1 bound to eIF4E (Figure 4c). Western blot analysis
Figure 4 Metformin affects protein translation. (a) Jurkat cells were cultured for 48 h in the absence (CTRL) or in the presence of either rapamycin
(500 nM) or metformin (5 mM). The polysome profile was generated by the measurement of optical density (OD) at 254 nm. (b) T-ALL cell lines
were grown in the absence (CTRL) or in the presence of the drugs for 48 h, then pulse-labeled for 4 h with (3H)-leucine at 2mCi/ml (0.074 MBq/ml)
in leucine-free medium. Results are the mean of three separate experiments±s.d. Asterisks indicate significant differences (*Po0.05; **Po0.01)
relative to CTRL. (c) Jurkat cells were cultured for 48 h without (CTRL) or with rapamycin (RAPA, 500 nM) or metformin (MET, 5 mM). A total of
5 106 cells were lysed in 600ml of solubilization buffer. Lysates were clarified by centrifugation, and supernatants were incubated with 7methyl-
GTP-Sepharose beads in 400ml binding buffer. Beads were then washed three times in binding buffer and boiled in sample buffer. Protein levels
were analyzed by western blot. (d) The polysomal fractions of Jurkat cells were pooled and the total RNA was isolated. Quantitative real-time PCR
to determine the c-Myc and Bcl-xL mRNA expression in polysomal fractions was carried out using b-actin as a control. Metformin was employed at
5 mM and rapamycin at 500 nM. Data are expressed as fold change as compared with untreated samples (CTRL) and represent means±s.d. of three
independent experiments (*Po0.05). (e) Western blot analysis for c-Myc and Bcl-xL in Jurkat cells treated with either metformin (MET, 5 mM) or
rapamycin (RAPA, 500 nM) for 48 h. CTRL: untreated cells.
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on whole-cell lysates demonstrated that the drugs did not
significantly reduce the total amounts of eIF4G, eIF4E, or 4E-BP1
(Figure 4c). In addition, when mRNA translation for two highly
oncogenic proteins (c-Myc and Bcl-xL) was directly analyzed in
the polysomal fractions, we found suppression by metformin,
but not rapamycin, in both Jurkat and CEM-R cells (Figure 4d).
Consistently, a metformin-dependent downregulation of c-Myc
and Bcl-xL protein expression was documented in Jurkat cells by
western blot (Figure 4e).
Metformin targets the side population of T-ALL cell lines
We sought to determine whether metformin could target the
T-ALL side population (SP). This subpopulation, which over-
expresses ABCG2 (also referred to as breast cancer resistance
protein or BRCP) and other ABC plasma membrane transporters,
is thought to share some properties of cancer stem cells
(CSCs).31 This has been documented in AML32 and multiple
myeloma.33 However, candidate CSCs have been successfully
identified also in the SP of a murine model of adult T-cell
leukemia/lymphoma.34 The SP of T-ALL cells was identified by
the live-cell DNA-binding dye, Hoechst 33342. As a control,
Hoechst 33342 staining could be inhibited after incubation
with the high-specificity ABCG2 transporter inhibitor, KO143.
A decrease in the amount of SP cells was evident in both
MOLT-4 and BE-13 cell lines treated for 24 h with 5 mM
metformin (Figure 5).
T-ALL lymphoblasts are sensitive to metformin
To better assess the efficacy of metformin as a potential
therapeutic agent in T-ALL, we examined pediatric and adult
T-ALL patient samples isolated from bone marrow or peripheral
blood, for their sensitivity to metformin, using MTT assays,
western blot and flow cytometry experiments. All of the patients
displayed enhanced phosphorylation of Thr 37/46 p-4E-BP1 and
Ser 235/236 p-S6RP (not shown). T-ALL lymphoblast samples
were treated with increasing concentrations of metformin, and
cell survival was analyzed by MTT assays. A marked reduction
of cell viability at 96 h was detected. The metformin IC50 for
patient samples ranged between 0.6 and 0.9 mM at 96 h
(Figure 6a). Western blot experiments demonstrated a strong
increase in Thr 172 p-AMPKa after 48 h of treatment with 1 mM
metformin. At the same time, phosphorylation of 4E-BP1 and
S6RP markedly decreased (Figure 6b). These observations were
confirmed by flow cytometric analysis (Figure 6c). Similar to the
results obtained using T-ALL cell lines, the regulation of Ser 473
p-Akt levels upon metformin treatment was variable (Figure 6b
and c).
Overall, these findings demonstrated that metformin dis-
played cytotoxic activity also against primary cells from T-ALL
patients.
Metformin induces apoptosis in the CD34þ /CD7/
CD4 subset of patient lymphoblasts
Finally, we investigated whether metformin could induce
apoptosis in a T-ALL patient lymphoblast subpopulation
(CD34þ /CD7/CD4), which is enriched in putative LIC,35
using quadruple staining and flow cytometric analysis.
After electronic gating on the CD7/CD4 lymphoblast subset,
cells were analyzed for CD34 expression and positivity to
Annexin V staining. After 72 h of treatment, metformin markedly
induced apoptosis in the CD34þ /CD7/CD4 subpopulation
(Figure 6d). Intriguingly, rapamycin was much less efficacious in
this respect. Also in this subpopulation, metformin was capable
of decreasing phosphorylation levels of 4E-BP1, S6RP and Akt
(Figure 6e).
Discussion
T-ALL is characterized by leukemic transformation of thymo-
cytes caused by cooperative events altering proliferation,
survival and differentiation of T cells. Despite major improve-
ments in our understanding of the molecular genetics of
T-ALL,36–39 the mechanisms that lead to the abnormal prolifera-
tion and survival of T-lymphoblasts remain largely unknown.
Therefore, treatment of this neoplasm remains a challenge for
clinicians. Major efforts have been made to develop new
compounds targeting signaling pathways implicated in T-ALL
cell proliferation and survival. The AMPK1/mTORC1 axis
represents a recently identified promising therapeutic target in
a number of tumors, as its activity is frequently deregulated in
cancer cells. Constitutive activation of mTORC1 is a common
event in T-ALL,40 which emphasizes the potential of using
mTORC1-targeting drugs as therapeutic agents in this disorder.
In preclinical models of T-ALL, the efficacy of the mTORC1
inhibitor, rapamycin, appears weak, at least in monotherapy
settings.41 Indeed, allosteric mTORC1 inhibitors such as
rapamycin and its derivatives do not target 4E-BP1 in T-ALL
cells and this limits their efficacy.12 In this study, we tested the
anti-leukemic activity of metformin on T-ALL cells, as recent
data have highlighted that this drug targets 4E-BP1-dependent
translation in AML.20 Metformin demonstrated marked anti-
leukemic effects in vitro against both T-ALL cell lines and
patients lymphoblasts. The cytotoxic effects were specific to
leukemic cells, as metformin only slightly affected the prolifera-
tion of CD4þ T-lymphocytes from healthy donors, in agree-
ment with a previous report, in which the AMPK activator
acadesine (AICAR) was tested on healthy T-lymphocytes.42
Moreover, metformin spared normal hematopoiesis ex vivo,
while it affected the clonogenic activity of AML CD34þ cells.20
Taken together, these findings suggest that targeting the
Figure 5 Metformin targets the SP in T-ALL cell lines. Cells were
treated with metformin (5 mM) for 24 h, then processed for SP analysis
by staining with Hoechst 33343 dye (5 mg/ml) followed by flow
cytometry. To gate SP cells, untreated (CTRL) cells were stained with
the Hoechst dye in the presence or in the absence of the ABCG2
blocking agent, KO-143 (0.1mM). Cells, which disappeared in the
presence of KO-143, were gated as the SP and are indicated as a
percentage of the whole viable cell population.
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AMPK/mTORC1 pathway in acute leukemias could result in a
favorable therapeutic window also in vivo.
Metformin-induced autophagy in T-ALL cells, which could be
due to inhibition of ULK1 and Atg13 phosphorylation by
mTORC1. Indeed, ULK1 and Atg13 are two essential compo-
nents of the autophagic machinery.43 Nevertheless, it should be
considered that ceramide has emerged as a negative regulator of
autophagy.44 Considering that metformin activated AMPK and
decreased ceramide levels in cardiomyocytes,45 it would be
interesting in the future to investigate the exact role of
sphingolipids in metformin-elicited autophagy in T-ALL cells.
As expected, metformin strongly inhibited mTORC1 signal-
ing, as evidenced by the decrease of p-p70S6K, p-S6RP and
p-4E-BP1, at residues that are recognized substrates of
mTORC1. However, in CEM-R cells, metformin treatment
resulted in increased levels of Ser 473 p-Akt, most likely
through mechanisms which involve IGF-1R, IRS2 and PI3K.
Accordingly, the anti-proliferative action of metformin could be
increased in CEM-R by a combination therapy consisting of
either a PI3K-selective inhibitor or a blocking monoclonal
antibody to IGF-1R.
In contrast, in Jurkat cells metformin actually decreased Ser
473 p-Akt. At present, we do not have an explanation for this
phenomenon. Nevertheless, similar effects of metformin on Ser
473 p-Akt levels have been reported in breast cancer cells,
where the drug dowregulated IRS1 at Ser 789, a site previously
Figure 6 Metformin exerts cytotoxicity towards T-ALL primary cells displaying constitutive activation of mTORC1 signaling, and targets the
CD34þ /CD7/CD4 lymphoblast subpopulation. (a) MTT assay of T-ALL lymphoblasts treated with metformin for 96 h. Results are the mean of at
least two different experiments±s.d. Three representative patients are shown. (b) Western blot analysis for p-AMPKa, p-4E-BP1, p-S6RP and p-Akt
in T-ALL lymphoblasts. One representative patient is shown. (c) Samples from T-ALL patients were analyzed by flow cytometry for the levels of
p-4E-BP1, p-S6RP and p-Akt in the absence (CTRL, black histograms) and presence (MET, white histograms) of 1 mM metformin for 24 h. Two
representative patients are shown. (d) Patient samples were incubated without (CTRL) or with either metformin (MET, 1 mM) or with rapamycin
(RAPA, 500 nM) for 48 h. After electronic gating on the CD7/CD4 lymphoblast subset, cells were analyzed for CD34 expression and positivity to
Annexin V staining. One representative of three different patients is shown. (e) The CD34þ /CD7/CD4 lymphoblast sub-population was stained
for p-4E-BP1, p-S6RP and p-Akt using AlexaFluor 488-conjugated antibodies. White histograms, untreated cells. Black histograms, cells treated
with 1 mM metformin for 48 h. One representative patient is shown.
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reported to inhibit downstream PI3K/Akt signaling.46 However,
our unpublished data reveal that metformin did not increase Ser
789 p-IRS1 in Jurkat cells.
The critical mechanism underlying metformin action in T-ALL,
however, may result from the inhibition of protein translation.
It has been recently emphasized that the weak anti-leukemic
activity of the rapamycin/rapalogues was mainly due to the sus-
tained high level of 4E-BP1 phosphorylation in AML and T-ALL
cells treated with these compounds.12,47 We showed herein that,
in contrast to rapamycin, metformin markedly inhibited the
assembly of eIF4F-initiating complexes and reduced the recruit-
ment of mRNA molecules to polysomes in T-ALL cells. This
resulted in an inhibition of protein synthesis and a decreased
expression of oncogenic proteins (c-Myc and Bcl-xL) known for
being regulated at the translation initiation level.
The difficulty in eradicating tumors might result from the
conventional treatments targeting the bulk of the tumor cells,
but not the CSC or LIC, in case of leukemias.48 Therefore,
strategies that eliminate these cells could have significant
clinical implications. On one side we were able to demonstrate
that metformin targeted the SP of T-ALL cells, which could be
enriched in CSCs. On the other side, metformin-induced
apoptosis in a T-ALL lymphoblast subpopulation (CD34þ /
CD7/CD4), which has been reported to be enriched in LIC
in pediatric patients. Intriguingly, rapamycin was not as effec-
tive in this respect. It should be pointed out that the CD34þ /
CD7/CD4 subpopulation is probably not the only cell
subset endowed with LIC activity in T-ALL.49 Therefore, other
T-ALL subpopulations in which LIC activity has been identified,
should be tested for their sensitivity to metformin.50 In any
case, it should be emphasized that in preclinical models of
breast cancer, metformin displayed a sensitivity for CSCs over
healthy cells.51
Previous investigations have highlighted the cytotoxic poten-
tial of the AMPK activator, AICAR in T-ALL and B-ALL cell
lines.52–54 However, as far as we know, this is the first report
that documents the cytotoxicity of metformin against both
T-ALL cell lines and patients lymphoblasts, including cell
subsets that could be enriched in LIC. Nevertheless, a word
of caution is necessary. In all the preclinical studies, which
have been performed to explore the in vitro antineoplastic
activity of metformin, the drug has shown efficacy in the lower
millimolar rage (1–10 mM). Also in our preclinical models
of T-ALL, the in vitro IC50 for metformin ranged from 1.6 to
5.6 mM in cell lines and from 0.6 to 0.9 mM in T-ALL patient
samples. The plasma metformin concentration in clinical use for
diabetic patients is B10 mM and normally does not exceed
50mM.55 Therefore, higher concentrations could be toxic to
normal cells. However, it is encouraging that when metformin
was combined with doxorubicin in preclinical models of
breast cancer, there was a strong synergism and the drug was
effective at a concentration (0.1 mM) that was not toxic to
untransformed cells.51 It is also intriguing that in this study, the
combined treatment reduced tumor mass and prevented
tumor relapse more effectively that either drug alone in a
xenograft mice model. Mice remained tumor free for at least
2 months after the combined treatment was ended. Moreover, a
recent study56 has documented that the positive charge of
metformin could promote its accumulation within the mitochon-
drial matrix by 1000-fold (420 mM). It has also been demon-
strated that metformin accumulates in tissues at concentra-
tions several fold higher than those in blood,57 indicating that
AMPK-related active concentrations of metformin employed
in preclinical settings might be attained also during cancer
treatment in humans.
The relevance of AMPK as a potential target for innovative
therapy of T-ALL is also underscored by a recent study, which
has documented that in a mouse T-ALL model, overexpressed
miR-19 led to downregulation of several target genes, including
PTEN, PP2A subunit B56e and Prkka1, which encodes for
AMPK. This resulted in stimulation of PI3K/Akt/mTORC1
signaling through different mechanisms.58
Several clinical trials of metformin as a cancer therapy
have been completed or are currently ongoing (http://www.
clinicaltrials.gov), mainly as a neoadjuvant therapy in breast
and prostate cancer. However, a clinical trial is underway in
which metformin was combined with vincristine, dexametha-
sone, doxorubicin and PEG–asparaginase for relapsed child-
hood ALL (NCT01324180). These trials support the feasibility of
using metformin in cancer patients, although the optimal
concentrations of this drug required for achieving antitumor
activity in vivo have yet to be determined. Overall, our findings
document a potent anti-tumor role for the LKB1/AMPK/
mTORC1 pathway in T-ALL, which is markedly activated by
metformin and involves the repression of mTORC1-dependent
oncogenic mRNA translation. Moreover, from the perspective of
clinical development, metformin barely impacted upon the
proliferation of CD4þT-lymphocytes from healthy donors,
strongly indicative of a favorable therapeutic index in vivo.
We have thus provided a strong rationale for the development of
AMPK agonists as novel therapeutic agents for T-ALL patients.
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